

December 21, 2013

Dear Editor,

Please find enclosed the edited manuscript in Word format (file name 5987-review.doc).

Title: Immunosuppressive Therapies for Inflammatory Bowel Disease

Authors: Talia Zenlea, Mark A. Peppercorn

Name of Journal: *World Journal of Gastroenterology*

ESPS Manuscript NO: 5987

The manuscript has been improved according to the suggestions of reviewers:

1 Revision has been made according to the suggestions of the reviewers:

1. Reviewer 00058695 made a number of suggestions, all of which were incorporated. Please see the text, where they are highlighted as "tracked changes."

These changes include:

- page 3 word 6048: note about the narrow therapeutic range of cyclosporine
 - page 5 word 2658: changed wording regarding availability of CTZ in various countries
 - page 5 word 3211: updated the vedolizumab reference to the one suggested
 - page 6 word 3342: added a paragraph on the UC SUCCESS data
 - page 2 word 1126: moved and reworded the section on hepatosplenic t cell lymphoma
 - page 6 word 3412: conclusion added
 - Minor stylistic corrections were made as suggested
2. Reviewer #00227519 suggested adding a section discussing the hazards of anti-TNF use in the peri-operative setting. We believe that this is a very interesting topic, but perhaps beyond the scope of the current review. If the editors feel that an additional section on this topic should be included, we would be happy to do so.

Thank you again for publishing our manuscript in the *World Journal of Gastroenterology*.

Sincerely yours,



Talia Zenlea, MD

Director of Inflammatory Bowel Diseases,

The Women's Medicine Collaborative

146 West River St, Providence, RI 02904.

taliazenlea@gmail.com

Tel: 401-793-7080

Fax: 401-793-7801